Industry news that matters to you.  Learn more

Archives for August 2014

Omicia and LabCorp Collaborate to Offer Comprehensive Genomic Analysis Services for Next-Generation Clinical Trials

Omicia, Inc. recently announced that Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America® Holdings (LabCorp®) for its clinical trials sequencing services. LabCorp’s broad menu of testing services, combined with Omicia’s flexible, powerful, and easy-to-use genome analysis platform, will allow the companies to provide a comprehensive suite of expert tools and services for incorporating genomic data into clinical trials. Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data, and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers can also store, analyze, and manage their clinical trial data within a highly secure environment.

Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, and Flagship Biosciences LLC, a leading tissue-based companion diagnostics firm, recently announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy (DMD) drug pipeline, including its lead candidate, eteplirsen.

Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc.

Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, recently announced a collaboration with TESARO, Inc. Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO’s TSR-011. This may lead to more successful clinical trial outcomes as well as enable Paradigm to develop and commercialize potential diagnostic products.

Nodality, Inc. Announces Publication of Promising Data in Melanoma in Journal of Translational Medicine

Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional systems biology, recently announced promising data utilizing the company’s proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality’s SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents. According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality’s researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

Massachusetts General Hospital is Newest SOMAscan Assay Site

SomaLogic, Inc., recently announced that Massachusetts General Hospital (MGH) will be the first Boston-area biomedical research center to perform on-site studies using the SOMAscan™ assay, a breakthrough proteomics platform that can measure more than a thousand proteins in a small amount of blood or other biological sample. The SOMAscan assay will be performed under the direction of Robert Gerszten, MD, Director of Clinical and Translational Research of the MGH Heart Center and Professor of Medicine at Harvard Medical School. It is expected that the SOMAscan assay will be installed and fully functional at MGH by mid-fall of 2014.